NVONovo Nordisk A/S
$38.62-35% 1Y
$38.62
$34.7652 weeks$61.72
Is the price fair?
What NVO's price assumes
Novo Nordisk A/S has no trailing P/E on file, so the price is measured against sales instead: 0.22× revenue.
0.22
Price / sales · no trailing P/E on file: measured against sales instead
- Price / book
- 1.12
Price / book · as of 2025-FY
- EV / sales
- 0.32
EV / sales
Details›
- Price / bookas of 2025-FY
- 1.12
- EV / EBITas of 2025-FY
- 0.74
- EV / salesas of 2025-FY
- 0.32
- Market capitalisation
- $210.9B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, General
Ranks #1 of 7 by RyuScore